News Alcon claims control of cell therapy firm Aurion Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive.
Oncology Patient-focused manufacturing models for personalised therap... In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine.
R&D JP Morgan Week 2025 – Paul Hastings At JP Morgan last month, pharmaphorum caught up with Paul Hastings, the CEO of Nkarta, to talk about NK cells and autoimmune diseases.
Oncology Access to cells for CGT is closer than you think So far, advanced therapy developers have been focusing on partnerships with specific hospitals for collecting patient cellular materials, and there are long-term concerns over the ability f
R&D Partner Content 4th Cell Therapy Potency Assay Summit In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical.
Oncology ASCO 2024 - Warner Biddle and Ibrahim Elhoussieny ASCO is always an interesting show for Kite, the Gilead Sciences subsidiary focused on cell therapy.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
